JPWO2020163325A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020163325A5 JPWO2020163325A5 JP2021544864A JP2021544864A JPWO2020163325A5 JP WO2020163325 A5 JPWO2020163325 A5 JP WO2020163325A5 JP 2021544864 A JP2021544864 A JP 2021544864A JP 2021544864 A JP2021544864 A JP 2021544864A JP WO2020163325 A5 JPWO2020163325 A5 JP WO2020163325A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- nme7
- seq
- peptide
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024171198A JP2025020113A (ja) | 2019-02-04 | 2024-09-30 | 抗ｎｍｅ抗体および癌または癌転移の治療方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962800941P | 2019-02-04 | 2019-02-04 | |
| US62/800,941 | 2019-02-04 | ||
| US201962830768P | 2019-04-08 | 2019-04-08 | |
| US62/830,768 | 2019-04-08 | ||
| US201962840769P | 2019-04-30 | 2019-04-30 | |
| US62/840,769 | 2019-04-30 | ||
| US202062965035P | 2020-01-23 | 2020-01-23 | |
| US62/965,035 | 2020-01-23 | ||
| PCT/US2020/016570 WO2020163325A1 (en) | 2019-02-04 | 2020-02-04 | Anti-nme antibody and method of treating cancer or cancer metastasis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024171198A Division JP2025020113A (ja) | 2019-02-04 | 2024-09-30 | 抗ｎｍｅ抗体および癌または癌転移の治療方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022519120A JP2022519120A (ja) | 2022-03-18 |
| JPWO2020163325A5 true JPWO2020163325A5 (https=) | 2023-04-05 |
| JP2022519120A5 JP2022519120A5 (https=) | 2023-04-05 |
| JP7695193B2 JP7695193B2 (ja) | 2025-06-18 |
Family
ID=71947215
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021544864A Active JP7695193B2 (ja) | 2019-02-04 | 2020-02-04 | 抗ｎｍｅ抗体および癌または癌転移の治療方法 |
| JP2024171198A Pending JP2025020113A (ja) | 2019-02-04 | 2024-09-30 | 抗ｎｍｅ抗体および癌または癌転移の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024171198A Pending JP2025020113A (ja) | 2019-02-04 | 2024-09-30 | 抗ｎｍｅ抗体および癌または癌転移の治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12037413B2 (https=) |
| EP (1) | EP3920693A4 (https=) |
| JP (2) | JP7695193B2 (https=) |
| KR (1) | KR20220016802A (https=) |
| CN (2) | CN117264064A (https=) |
| AU (1) | AU2020219046A1 (https=) |
| CA (1) | CA3128384A1 (https=) |
| IL (1) | IL285352A (https=) |
| WO (1) | WO2020163325A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106414726A (zh) | 2014-04-07 | 2017-02-15 | 米纳瓦生物技术公司 | 抗nme抗体 |
| EP3920693A4 (en) | 2019-02-04 | 2022-10-05 | Minerva Biotechnologies Corporation | ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS |
| CN116367857A (zh) | 2020-06-08 | 2023-06-30 | 米纳瓦生物技术公司 | 抗nme抗体及治疗癌症或癌症转移的方法 |
| KR20230028796A (ko) * | 2020-06-26 | 2023-03-02 | 미네르바 바이오테크놀로지 코포레이션 | 항-nme 항체 및 암 또는 암 전이의 치료 방법 |
| KR20250009592A (ko) | 2022-04-12 | 2025-01-17 | 미네르바 바이오테크놀로지 코포레이션 | 항-가변 muc1* 항체 및 그의 용도 |
| WO2025049494A1 (en) | 2023-08-29 | 2025-03-06 | Minerva Biotechnologies Corporation | Bacterial nme7 orthologs and uses thereof |
| CN119931939B (zh) * | 2025-04-08 | 2025-08-15 | 上海交通大学医学院附属仁济医院 | 一种提升i型经典树突状细胞亚群诱导效率的方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874285A (en) | 1996-09-13 | 1999-02-23 | Incyte Pharmaceuticals, Inc. | Polynucleotide encoding a novel human nm23-like protein |
| US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
| CA2384713A1 (en) | 1999-09-29 | 2001-04-05 | Human Genome Sciences, Inc. | Colon and colon cancer associated polynucleotides and polypeptides |
| CA2491017A1 (en) | 2002-07-03 | 2004-01-15 | Immunogen, Inc. | Antibodies to non-shed muc1 and muc16, and uses thereof |
| WO2004050860A2 (en) | 2002-12-04 | 2004-06-17 | Diadexus, Inc. | Compositions, splice variants and methods relating to colon specific genes and proteins |
| CA2611728A1 (en) * | 2005-06-08 | 2006-12-14 | Millennium Pharmaceuticals, Inc. | Methods for the identification, assessment, and treatment of patients with cancer therapy |
| US20100254996A1 (en) | 2007-06-18 | 2010-10-07 | Medimmune, Llc | Synergistic treatment of cells that express epha2 and erbb2 |
| DK2334703T3 (en) | 2008-09-17 | 2015-10-05 | Innate Pharma | Configurations and methods for detection of tlr3 |
| US20170204191A1 (en) | 2008-10-06 | 2017-07-20 | Cynthia C. Bamdad | Muc1* antibodies |
| US20110195089A1 (en) * | 2008-10-08 | 2011-08-11 | The Adminstrators Of The Tulane Educational Fund | Compositions, methods, and kits for enhancing the immunogenicity of pathogenic antigens |
| SG176801A1 (en) | 2009-06-11 | 2012-01-30 | Minerva Biotechnologies Corp | Methods for culturing stem and progenitor cells |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP2768945B1 (en) | 2011-10-17 | 2022-01-05 | Minerva Biotechnologies Corporation | Media for stem cell proliferation and induction |
| CA2864872C (en) * | 2012-02-24 | 2022-07-05 | Alteogen Inc. | Modified antibody in which motif comprising cysteine residue is bound |
| AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| CN111849874A (zh) | 2012-07-24 | 2020-10-30 | 米纳瓦生物技术公司 | Nme变体物种表达和抑制 |
| CN104717980A (zh) | 2012-08-14 | 2015-06-17 | 米纳瓦生物技术公司 | 干细胞增强疗法 |
| CA2886161A1 (en) | 2012-09-29 | 2014-04-03 | The Trustees Of The University Of Pennsylvania | Veterinary composition and methods for non-surgical neutering and castration |
| IL240695B2 (en) | 2013-02-20 | 2024-03-01 | Minerva Biotechnologies Corp | Nme inhibitors and methods of using nme inhibitors |
| US20160326263A1 (en) | 2013-02-20 | 2016-11-10 | Minerva Biotechnologies Corporation | NME Inhibitors and Methods of Using NME Inhibitors |
| CN106414726A (zh) | 2014-04-07 | 2017-02-15 | 米纳瓦生物技术公司 | 抗nme抗体 |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| WO2018010140A1 (zh) | 2016-07-14 | 2018-01-18 | 中国科学院生物物理研究所 | I型干扰素受体抗体及其用途 |
| WO2018054240A1 (en) | 2016-09-20 | 2018-03-29 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pcsk9 antibodies |
| JP2020500031A (ja) * | 2016-10-11 | 2020-01-09 | ミネルバ バイオテクノロジーズ コーポレーション | ヒト化抗ｍｕｃ１＊抗体及び開裂酵素の使用 |
| WO2019104306A1 (en) | 2017-11-27 | 2019-05-31 | Minerva Biotechnologies Corporation | Humanized anti-muc1* antibodies and direct use of cleavage enzyme |
| EP3920693A4 (en) | 2019-02-04 | 2022-10-05 | Minerva Biotechnologies Corporation | ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS |
| CN116367857A (zh) | 2020-06-08 | 2023-06-30 | 米纳瓦生物技术公司 | 抗nme抗体及治疗癌症或癌症转移的方法 |
| KR20230028796A (ko) | 2020-06-26 | 2023-03-02 | 미네르바 바이오테크놀로지 코포레이션 | 항-nme 항체 및 암 또는 암 전이의 치료 방법 |
-
2020
- 2020-02-04 EP EP20752059.4A patent/EP3920693A4/en active Pending
- 2020-02-04 CA CA3128384A patent/CA3128384A1/en active Pending
- 2020-02-04 AU AU2020219046A patent/AU2020219046A1/en active Pending
- 2020-02-04 WO PCT/US2020/016570 patent/WO2020163325A1/en not_active Ceased
- 2020-02-04 JP JP2021544864A patent/JP7695193B2/ja active Active
- 2020-02-04 CN CN202311184872.3A patent/CN117264064A/zh active Pending
- 2020-02-04 CN CN202080024809.1A patent/CN113727602B/zh active Active
- 2020-02-04 KR KR1020217028113A patent/KR20220016802A/ko active Pending
-
2021
- 2021-08-03 US US17/392,981 patent/US12037413B2/en active Active
- 2021-08-03 IL IL285352A patent/IL285352A/en unknown
-
2024
- 2024-06-03 US US18/731,929 patent/US20240392038A1/en active Pending
- 2024-09-30 JP JP2024171198A patent/JP2025020113A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7682789B2 (ja) | Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用 | |
| JP2013502913A5 (https=) | ||
| JP2020533311A5 (ja) | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 | |
| JP2020525032A5 (https=) | ||
| JP2019507762A5 (https=) | ||
| JP2019536430A5 (https=) | ||
| JP2013500703A5 (https=) | ||
| JP2012523848A5 (https=) | ||
| JP2021510521A5 (https=) | ||
| IL303554A (en) | Anti-sirpa antibody and application thereof | |
| JP2013544756A5 (https=) | ||
| JP2006020633A (ja) | 糸球体腎炎および他の炎症性疾患の治療のための組成物および方法 | |
| JP2010504755A5 (https=) | ||
| Imakiire et al. | Generation, immunologic characterization and antitumor effects of human monoclonal antibodies for carcinoembryonic antigen | |
| JP2018505681A5 (https=) | ||
| JP2012519492A5 (https=) | ||
| JP2010523592A5 (https=) | ||
| JP2017537082A5 (https=) | ||
| JP2024016024A5 (https=) | ||
| CN108025064A (zh) | 抗磷脂酰肌醇蛋白聚糖-3抗体和其用于诊断与治疗癌症的用途 | |
| JP2021518415A5 (https=) | ||
| JP2021512604A5 (https=) | ||
| JP2016529213A5 (https=) | ||
| JPWO2020163325A5 (https=) | ||
| JP2021529524A5 (https=) |